Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-15469A (Moxifloxacin) for Bacterial Conjunctivitis
NCT00331916Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Nov 2005
- Primary completion
- May 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial conjunctivitis (BC) comparing Moxifloxacin AF with Vehicle (2 arms). Primary endpoint: Clinical cure and microbiological success at Day 7. Started Nov 2005; status: completed.
02
Drugs
moxifloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT00331916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331916.